Skip to main content
Journal cover image

Ranibizumab in Myopic Choroidal Neovascularization: A Subgroup Analysis by Ethnicity, Age, and Ocular Characteristics in RADIANCE.

Publication ,  Journal Article
Holz, FG; Tufail, A; Leveziel, N; Lai, TYY; Lanzetta, P; Wong, TY; Yu, HG; Chen, YX; Heinrichs, N; Pilz, S; Ohno-Matsui, K; RADIANCE Study Group,
Published in: Ophthalmologica
2016

PURPOSE: To assess the impact of ethnicity, age, and ocular characteristics on ranibizumab efficacy in myopic choroidal neovascularization (CNV). METHODS: In this post hoc subgroup analysis from the phase III RADIANCE study, best-corrected visual acuity (BCVA) outcomes and treatment exposure were analyzed in 105 patients treated with ranibizumab 0.5 mg. Baseline categories included ethnicity, age, baseline BCVA, lesion area, CNV lesion area, refraction sphere, axial length, subretinal fluid, and location of CNV. RESULTS: At month 12, the mean change in BCVA was numerically higher in East-Asians than in Caucasians (17.0 vs. 14.1 letters). The median number of injections varied with ethnicity (East-Asians vs. Caucasians: 2 vs. 3), baseline BCVA (highest vs. lowest: 1 vs. 4), CNV lesion area and lesion area (largest vs. smallest: 5 vs. 1 and 5 vs. 2). CONCLUSIONS: East-Asians showed numerically higher BCVA gains than Caucasians. The number of injections varied across subgroups, emphasizing the need for individualized treatment.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ophthalmologica

DOI

EISSN

1423-0267

Publication Date

2016

Volume

236

Issue

1

Start / End Page

19 / 28

Location

Switzerland

Related Subject Headings

  • Visual Acuity
  • Vascular Endothelial Growth Factor A
  • Treatment Outcome
  • Tomography, Optical Coherence
  • Risk Factors
  • Retina
  • Ranibizumab
  • Ophthalmology & Optometry
  • Myopia, Degenerative
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Holz, F. G., Tufail, A., Leveziel, N., Lai, T. Y. Y., Lanzetta, P., Wong, T. Y., … RADIANCE Study Group, . (2016). Ranibizumab in Myopic Choroidal Neovascularization: A Subgroup Analysis by Ethnicity, Age, and Ocular Characteristics in RADIANCE. Ophthalmologica, 236(1), 19–28. https://doi.org/10.1159/000446027
Holz, Frank G., Adnan Tufail, Nicolas Leveziel, Timothy Y. Y. Lai, Paolo Lanzetta, Tien Y. Wong, Hyeong Gon Yu, et al. “Ranibizumab in Myopic Choroidal Neovascularization: A Subgroup Analysis by Ethnicity, Age, and Ocular Characteristics in RADIANCE.Ophthalmologica 236, no. 1 (2016): 19–28. https://doi.org/10.1159/000446027.
Holz FG, Tufail A, Leveziel N, Lai TYY, Lanzetta P, Wong TY, et al. Ranibizumab in Myopic Choroidal Neovascularization: A Subgroup Analysis by Ethnicity, Age, and Ocular Characteristics in RADIANCE. Ophthalmologica. 2016;236(1):19–28.
Holz, Frank G., et al. “Ranibizumab in Myopic Choroidal Neovascularization: A Subgroup Analysis by Ethnicity, Age, and Ocular Characteristics in RADIANCE.Ophthalmologica, vol. 236, no. 1, 2016, pp. 19–28. Pubmed, doi:10.1159/000446027.
Holz FG, Tufail A, Leveziel N, Lai TYY, Lanzetta P, Wong TY, Yu HG, Chen YX, Heinrichs N, Pilz S, Ohno-Matsui K, RADIANCE Study Group. Ranibizumab in Myopic Choroidal Neovascularization: A Subgroup Analysis by Ethnicity, Age, and Ocular Characteristics in RADIANCE. Ophthalmologica. 2016;236(1):19–28.
Journal cover image

Published In

Ophthalmologica

DOI

EISSN

1423-0267

Publication Date

2016

Volume

236

Issue

1

Start / End Page

19 / 28

Location

Switzerland

Related Subject Headings

  • Visual Acuity
  • Vascular Endothelial Growth Factor A
  • Treatment Outcome
  • Tomography, Optical Coherence
  • Risk Factors
  • Retina
  • Ranibizumab
  • Ophthalmology & Optometry
  • Myopia, Degenerative
  • Middle Aged